These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

929 related articles for article (PubMed ID: 8935625)

  • 21. Electrochemotherapy as an adjunct or alternative to other treatments for unresectable or in-transit melanoma.
    Möller MG; Salwa S; Soden DM; O'Sullivan GC
    Expert Rev Anticancer Ther; 2009 Nov; 9(11):1611-30. PubMed ID: 19895245
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Malignant melanoma: conceptual and therapeutic innovations based on translational research].
    Piérard GE; Quatresooz P; Rorive A; Piérard-Franchimont C;
    Rev Med Liege; 2008 Oct; 63(10):579-84. PubMed ID: 19009964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Administration of high-dose interleukin-2 in a 2-year-old with metastatic melanoma.
    Bernhardt MB; Hicks MJ; Pappo AS
    Pediatr Blood Cancer; 2009 Dec; 53(7):1346-8. PubMed ID: 19731326
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BCG immunotherapy in patients with malignant melanoma.
    Karakousis CP; Douglass HO; Yeracaris PM; Holyoke ED
    Arch Surg; 1976 Jun; 111(6):716-8. PubMed ID: 776125
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Study and treatment of locally advanced melanoma].
    Moreno-Ramírez D; de la Cruz L; Ferrándiz L; Camacho FM
    Actas Dermosifiliogr; 2009 Nov; 100(9):767-79. PubMed ID: 19889298
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intralesional immunotherapy of melanoma with BCG.
    Rosenberg SA; Rapp HJ
    Med Clin North Am; 1976 May; 60(3):419-30. PubMed ID: 1271887
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current concepts review: management of melanoma.
    Rizk SN; Ryan JJ
    S D J Med; 1994 Jul; 47(7):217-21. PubMed ID: 7939573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination of HDAC inhibitor MS-275 and IL-2 increased anti-tumor effect in a melanoma model via activated cytotoxic T cells.
    Kato Y; Yoshino I; Egusa C; Maeda T; Pili R; Tsuboi R
    J Dermatol Sci; 2014 Aug; 75(2):140-7. PubMed ID: 24866536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of murine renal carcinoma pulmonary metastases by systemic administration of interferon gamma: mechanism of action and potential for combination with interleukin 4.
    Hillman GG; Younes E; Visscher D; Hamzavi F; Kim S; Lam JS; Montecillo EJ; Ali E; Pontes JE; Puri RK; Haas GP
    Clin Cancer Res; 1997 Oct; 3(10):1799-806. PubMed ID: 9815566
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential cell- and immuno-biological properties of murine B16-F1 and F10 melanomas: oncogene c-fos expression, sensitivity to LAK cells and/or IL-2, and components of gangliosides.
    Nakayama J; Urabe K; Tsuchida T; Urabe A; Terao H; Taniguchi S; Hori Y
    J Dermatol; 1995 Aug; 22(8):549-59. PubMed ID: 7560451
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemotherapy for metastatic melanoma.
    Mandarà M; Nortilli R; Sava T; Cetto GL
    Expert Rev Anticancer Ther; 2006 Jan; 6(1):121-30. PubMed ID: 16375649
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of human natural killer cells on the metastatic growth of human melanoma xenografts in mice with severe combined immunodeficiency.
    Hill LL; Perussia B; McCue PA; Korngold R
    Cancer Res; 1994 Feb; 54(3):763-70. PubMed ID: 8306339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictive factors for intrahepatic recurrence after percutaneous ethanol injection therapy for small hepatocellular carcinoma.
    Koda M; Murawaki Y; Mitsuda A; Ohyama K; Horie Y; Suou T; Kawasaki H; Ikawa S
    Cancer; 2000 Feb; 88(3):529-37. PubMed ID: 10649243
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic melanoma.
    Triozzi PL; Strong TV; Bucy RP; Allen KO; Carlisle RR; Moore SE; Lobuglio AF; Conry RM
    Hum Gene Ther; 2005 Jan; 16(1):91-100. PubMed ID: 15703492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Thermochemotherapy for malignant melanoma--combination therapy of ACNU and hyperthermia in mice].
    Yamada K; Someya T; Shimada S; Ohara K; Kukita A
    Gan To Kagaku Ryoho; 1983 Oct; 10(10):2179-87. PubMed ID: 6578704
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
    Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
    Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Melanoma and immunotherapy.
    Eggermont AM; Schadendorf D
    Hematol Oncol Clin North Am; 2009 Jun; 23(3):547-64, ix-x. PubMed ID: 19464602
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synergistic effects of hyperthermia and peplomycin against human malignant melanoma xenografts.
    Yamada K; Nakagawa H; Etoh T; Ishibashi Y
    J Dermatol; 1988 Oct; 15(5):405-11. PubMed ID: 2464632
    [No Abstract]   [Full Text] [Related]  

  • 39. Recurrent malignant proliferating trichilemmal tumour: local management with ethanol injection.
    Takenaka H; Kishimoto S; Shibagaki R; Nagata M; Noda Y; Yasuno H
    Br J Dermatol; 1998 Oct; 139(4):726-9. PubMed ID: 10025976
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma.
    Bajetta E
    Nat Clin Pract Oncol; 2008 Jan; 5(1):4-5. PubMed ID: 18043604
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.